Palisade Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Palisade Bio reported positive Phase 1 clinical trial results for its lead IBD drug candidate PALI-2108, secured $127.6 million in financing, and outlined plans for Phase 2 studies in 2026.
NASDAQ
Palisade Bio's 10-K filing reveals ongoing net losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidate PALI-2108.
NASDAQ
Palisade Bio pivots to pre-clinical development of PALI-2108 for inflammatory bowel disease after terminating its LB1148 program.